BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO) from its SEC filings: 2025 revenue $502.1 million (+126% vs the year before), free cash flow -$447.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $502.1 million |
| Revenue growth | +126% |
| Free cash flow | -$447.0 million |
| Diluted EPS | $-3.78 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +120% |
| Cash | $677.9 million |
| Long-term debt | $0 |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.